Over the last few years, hydrodynamic tail vein delivery has established itself as a simple, yet very effective method for gene transfer into small rodents. Hydrodynamic delivery of plasmid DNA expression vectors or small interfering RNA allows for a broad range of in vivo experiments, including the testing of regulatory elements, antibody generation, evaluation of gene therapy approaches, basic biology and disease model creation (non-heritable transgenics). The recent development of the hydrodynamic limb vein procedure provides a safe nucleic acid delivery technique with equally high efficiency in small and large research animals and, importantly, the prospects for clinical translation. Gene Therapy (2007) Hydrodynamic tail vein (HTV) delivery is highly efficient at transferring nucleic acids to the liver of mice and rats. This simple non-viral gene transfer procedure entails the rapid delivery of naked plasmid DNA (pDNA) in a relatively large volume of physiological solution. In a typical mouse, weighing 20 g, the pDNA is delivered in a total volume of 2.0 ml over a period of 5-7 s. These seemingly harsh conditions actually cause very little harm and are well tolerated. After the first description of this technique in 1999, there are now hundreds of published studies applying HTV. Although most studies have focused on pDNA delivery, it is clear that any naked polynucleotide can be delivered effectively, including small interfering RNA (siRNA). Here, we will highlight important recent research findings related to hydrodynamic delivery, including mechanistic studies, applications and the development of the clinically relevant hydrodynamic limb vein (HLV) delivery procedure.
Hydrodynamic tail vein delivery of naked plasmid DNA is the simplest and most effective non-viral gene delivery technique to liver in mice Hydrodynamic tail vein (HTV) delivery is highly efficient at transferring nucleic acids to the liver of mice and rats. This simple non-viral gene transfer procedure entails the rapid delivery of naked plasmid DNA (pDNA) in a relatively large volume of physiological solution. In a typical mouse, weighing 20 g, the pDNA is delivered in a total volume of 2.0 ml over a period of 5-7 s. These seemingly harsh conditions actually cause very little harm and are well tolerated. After the first description of this technique in 1999, there are now hundreds of published studies applying HTV. Although most studies have focused on pDNA delivery, it is clear that any naked polynucleotide can be delivered effectively, including small interfering RNA (siRNA). Here, we will highlight important recent research findings related to hydrodynamic delivery, including mechanistic studies, applications and the development of the clinically relevant hydrodynamic limb vein (HLV) delivery procedure.
Hydrodynamic injection increases intravascular pressure
A number of groups have taken up the task to elucidate the mechanism of hydrodynamic gene transfer. Recent
In brief Progress
Hydrodynamic tail vein delivery of naked plasmid DNA is the simplest and most effective non-viral gene delivery technique to the liver in mice. Hydrodynamic injection increases intravascular pressure. Hydrodynamic limb vein (HLV) delivery offers an efficient route for non-viral gene delivery to skeletal muscle. HLV delivery is a platform technology with equal efficiency in small and large research animals. HLV delivery provides a clear pathway to clinical gene delivery. Hydrodynamic delivery enables in vivo biological studies.
Prospects
More in vivo biological studies will employ hydrodynamic gene delivery. Hydrodynamic delivery will be used more frequently for gene delivery into large research animals. Hydrodynamic delivery methods will be increasingly used to generate animal disease models. Hydrodynamic delivery will be increasingly used for delivering siRNAs to research animals. HLV delivery will enter the clinic. Establishment of safety and efficacy of HLV delivery in humans will enable many gene therapy applications.
publications share a range of converging observations. It had been reasoned that upon rapidly injecting a solution into the tail vein, the fluids enter the vena cava where the fluids back up, as the large volume cannot be pumped rapidly enough through the heart. This creates increased pressure in the vena cava and pushes the pDNA solution into draining vasculature, in particular, the large hepatic vein. There, the fluid is forced out of the capillaries into the tissue and the nucleic acids (or other compounds present in the solution) enter into the parenchymal cells. In fact, one can readily observe the liver swell during a HTV delivery. Zhang et al. 1 argued that HTV delivery actually induces a transient heart failure that is accompanied by a decreased heart rate and an increased cardiac ventricular size (inferred from an increased QRS electrocardiography amplitude). The published data are suggestive of hemodynamic stress and distention of the right atrium, but studies employing echocardiography are indicated to determine better the impact of HTV delivery on the heart. Upon injection, an increase in the inferior vena cava pressure of approximately 40 mm Hg has been observed 1,2 (and our own unpublished work). As a result of the increased vena cava pressure, the pDNA solution back-fills the hepatic vein into the liver, practically mediating a transient inversion of the intrahepatic blood flow. 2 Although nucleic acid uptake and expression has been measured in all major organs, the majority (490%) is found in the liver. Two anatomic features account for this are as follows: (1) the liver has larger access vessels to the vena cava than other organs, absorbing the bulk of the injected pDNA solution; and (2) liver vessels contain a higher number of large pores (fenestrae), allowing for easier fluid/pDNA extravasation. The question remains how the nucleic acid enters the target cells. Effective HTV delivery is not limited to small (siRNA) and large (pDNA) nucleic acids, but extends to a range of other molecules including proteins, dyes and viruses. For instance, Zhang et al. 1 reported similar uptake efficiency and distribution patterns for pDNA (expression and distribution), b-galactosidase protein and Evans Blue dye. This is suggestive of a purely physical delivery method, excluding the involvement of receptor-mediated processes. However, an important caveat is that some of these molecules were taken up into heavily damaged hepatocytes. Such cells do not express reporter genes, suggesting that uptake is not indicative of a transport process that leads to foreign gene expression. 3, 4 Several studies suggest the formation of small pores in the cellular membrane during the rapid injection. 1, 5 The quick onset of elevated alanine aminotransferase and aspartate aminotransferase blood levels and release of cell-resident green fluorescent protein at 2 h after injection is also consistent with the appearance of membrane pores. 5 This is important in that it suggests that elevated liver enzymes may not indicate cell death. It has also been proposed that pDNA entry into hepatocytes can be achieved via pores that are induced by massaging the liver. 6 An alternative cellular entry route is indicated by the observations of Crespo et al. 2 and our group, 3, 4 indicating the presence of a large number of intracellular vesicles, but no obvious membrane defects. This suggests that cellular pDNA entry takes place via a microfluid uptake process. Evidence for persistent membrane pores was deduced from the ability to obtain substantial pDNA expression from pDNA injected under normal injection conditions, in mice that had been previously injected with normal saline under HTV conditions. 1, 5, 7 However, the delayed uptake of pDNA via vesicles is also consistent with this observation. It is possible that cells that are able to seal membrane pores and survive, take up pDNA both by direct cytoplasmic entry and by the vesicular mechanism. The expression of pDNA is restricted to hepatocytes. It is possible that sinusoidal cells do not survive the HTV procedure, but substantial damage to sinusoidal cells has not been observed. Another possibility is the absence of HTV-induced vesicles within these cells. Further study is needed to delineate the importance of each of these putative pathways and their inter-relationship in enabling uptake and expression in hepatocytes.
HLV delivery offers an efficient route for non-viral gene delivery to skeletal muscle HTV delivery mainly results in expression in the liver. Lower levels of expression (100-to 1000-fold) are found in the spleen, heart, kidneys and lungs. A similar distribution of transfection and expression can also be observed after delivery into the jugular vein of mice (our unpublished observations) and chickens. 8 In these studies, the needle itself acted as a block to prevent backflow. By delivering the pDNA solution directly into vessels supplying an organ, it is possible to direct a majority of the expression to that organ. Maruyama et al. 9, 10 demonstrated that delivery into the renal vein resulted in high reporter gene expression levels in the kidneys. Hydrodynamic injection into the common carotid artery led to transfection of 10-30% of the cells in brain tumors implanted in the frontal lobe of rats.
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Skeletal limb muscle tissues were transfected following HTV delivery, although occluding the aorta and vena cava, thus forcing the pDNA solution into the hindlimbs. 12 Such approaches allow for the testing of expression constructs in particular organs and will facilitate in vivo biological research. However, the surgical nature of these delivery approaches may prevent routine use. A method that is much more suited to widespread use in the research lab and the clinic is HLV delivery. 13 The principle of HLV is rapidly to deliver a nucleic acid solution into a limb vein while the blood flow in and out of the limb is blocked by a tourniquet (Figure 1 ). This technique is surprisingly simple (especially in larger research animals) and results in high gene transfer efficiency to skeletal muscle cells (10-40%).
HLV delivery is a platform technology with equal efficiency in small and large research animals
Many gene transfer techniques work well in small research animals, but show much lower efficiency in larger animals and humans. Probably the most attractive feature of HLV is that equal efficiencies have been observed in small (mouse, rat) and large (rabbit, dog, monkey) research animals. 13 For instance, luciferase expression 7 days after HLV gene delivery averaged 419 ng/g of muscle tissue in dog and 666 ng/g in rhesus monkey, compared with 577 ng/g in rat. 13 This method therefore promises to be a good candidate for non-viral human gene delivery. Similar observations were made with a precursor to HLV, where the pDNA solution is delivered into an artery. This technique is technically more complicated and less attractive for clinical applications, yet provides similar efficiencies in research animals. 13, 14 Using this hydrodynamic limb artery (HLA) delivery method in pigs, Danialou et al.
14 measured the correlation between intramuscular pressure and expression. Large variations in pressure were found between different muscles. There was a significant inverse relationship between intramuscular pressure and the subsequent level of gene transfer to muscle. This could be caused by a reduction of the microcirculatory flow with higher intramuscular pressure, thus reducing pDNA delivery. Modification of the injection protocol to reduce intramuscular pressure led to greatly increased pDNA-mediated gene expression and reduced muscle damage in pigs. Under optimal conditions, the average transfection efficiency within eight different muscles of the pig hindlimb was 22% of all fibers, with a maximum of 60% in the gastrocnemius. The authors concluded that intramuscular pressure monitoring is a simple and useful procedure to help optimize pDNA-mediated gene transfer to skeletal muscles by the HLA technique. We hypothesize that this may extend to the HLV technique as well.
HLV delivery provides a clear pathway to clinical gene delivery
In a commentary in Molecular Therapy, Wells 15 wrote that the HLV delivery procedure 'is the first clear demonstration of a clinically applicable protocol for the non-viral delivery of genetic material to multiple muscles groups. It opens the floodgates for a whole range of possible genetic manipulations of skeletal muscle ranging from basic research to clinical application, including the genetic manipulation of fiber phenotype, the use of a substantial muscle mass as a platform for local and/or systemic expression of a range of therapeutic proteins as well as the direct treatment of muscle diseases.' The lack of procedure-associated toxicity was further established in a study by Toumi et al. 16 demonstrating that the rapid extravasation of fluid during the injection process resulted in edema of the muscle tissue of the targeted limb. However, the edema was transient and resolved within 24 h. Minimal levels of myofiber damage were detected. Immunohistochemical labeling indicated that increased numbers of neutrophils (CD43 + ) and macrophages (ED1 + and ED2 + ) were present in the muscle 23, 24 organophosphate toxicity, 25 glomerulonephritis, 26 shortchain acyl-CoA dehydrogenase, 27 obesity, 28 (xeno)transplantation, 29, 30 metachromatic leukodystrophy, 31 hypoxic-ischemia encephalopathy 32 and multiple cancer gene therapy approaches. [33] [34] [35] [36] [37] The potential of HLV gene delivery is apparent from the work of Danko and co-workers. [38] [39] [40] They delivered pDNA expressing the human hepatic bilirubin uridine diphosphate-glucuronosyltransferase (hUGT1A1) to correct hyperbilirubinemia in the UGT1A1-deficient Gunn rat, an animal model of Crigler-Najjar syndrome type I (CN-I). The pDNA was delivered via the hepatic vein, the femoral artery or the great saphenous vein, resulting in detection of in vitro bilirubin glucuronidation activity in liver and muscle extracts. Expression of hUGT1A1 in Gunn rat liver or muscle resulted in excretion of bilirubin glucuronides in bile, with total serum bilirubin decreasing by about 30%. Such a decrease in serum bilirubin, if sustained, would provide meaningful clinical benefit for CN-I patients. The increase in excretion of bilirubin glucuronides in bile and a decrease in serum bilirubin lasted for 2-4 weeks. Monthly HLV gene delivery maintained metabolic correction for at least 5 months. 40 Animals expressing hUGT1A1 developed anti-hUGT1A1 antibodies and lymphocytic infiltrate in muscle. Immunosuppression abrogated antibody response, ameliorated lymphocytic inflammation and enhanced metabolic correction, but did not prevent a decrease in the amount of recombinant protein. Although this particular disease afflicts only a very small number of patients, it demonstrates proof-of-concept for gene therapy of metabolic disease, in particular, by expressing the therapeutic gene ectopically.
Our overall experience is that expression is stable in skeletal muscle after pDNA delivery as long as the expressed protein does not induce a cytolytic T-cell response. We have shown this with the intravascular delivery of pDNA expressing mouse dystrophin in mdx mice. Dystrophin expression was stable for at least 6 months following intra-arterial delivery. 41 More recent unpublished studies using the HLV procedure indicate mouse dystrophin expression for at least 1 year. Interestingly, antibodies are generated against the mouse dystrophin, but the intracellular dystrophin is presumably not accessible to the antibodies. A cellular immune response was not detected in these muscles. The HLV technique has not only been used successfully in the mdx mouse but in the golden retriever muscular dystrophy (GRMD) dog models for Duchenne muscular dystrophy. On the basis of these studies, we and our French co-workers are initiating a human clinical trial to express the full-length dystrophin in the forearms of patients with Duchenne so as to preserve hand function and improve the quality of life.
Evaluation of promoters and vectors in vivo enabled by HTV delivery
One of the holy grails of gene therapy is to provide lifelong expression of the delivered transgene following a single delivery. Unfortunately, many frequently used promoters (e.g., cytomegalovirus (CMV)) are turned off soon after gene delivery. 42 In vitro evaluation of expression vectors has been of low value in predicting in vivo expression vector performance. HTV pDNA delivery now allows the direct testing of many expression vector iterations in vivo. In a study comparing 10 commonly used promoters, the CMV promoter expressed 10-to 1000-fold higher levels of human a1-antitrypsin (hAAT) on day 7 than other commonly used promoters such as Rous sarcoma virus, phosphoglycerol kinase and albumin. 43 The only promoter expressing in the same range as CMV was the EF1 promoter. Other researchers have focused on the development of (recombinant) promoters capable of driving sustained, high-level expression. This has led to pDNA expression vectors that can express transgenes for very long time periods in the liver at levels that are at most 10-fold below those generated by CMV promoters in the first week after delivery. For instance, a vector expressing the full genomic hAAT gene with its natural promoter resulted in therapeutic and stable production of hAAT. 44 Similarly, a vector with liver-specific promoter and enhancer elements resulted in liver expression for at least 1 year. 45 Such sustained expression vectors demonstrate a slow decline in expression, presumably because of hepatocytes turnover. 17, 45 The half-life of these cells is estimated at 6-12 months. For that reason, there has been significant interest in vectors that mediate integration of the transgene expression cassette. The best-described system is Sleeping Beauty (SB), which has led to the development of other integration systems including Frog Prince, Tol2, phiC31 and L1. 46 The SB system consists of a transposon, made up of a gene of interest flanked by transposon inverted repeats, and a source of transposase. Inclusion of SB transposase at specific ratios to a hAAT integration vector provided a 100-fold increase in transgene expression for at least 2 months. 43 This may in part be due to a direct effect of the transposase on the transcriptional activity of the transgene expression cassette. 47 Integration efficiency can be greatly enhanced by CpG methylation of the transposon region. 48 Integration of SB transposons with respect to genes (exons and introns) and intergenic regions appears fairly random at the genomic level, but not on a micro-scale. 49 The sites used most often for integration appear to depend on a deformation inherent in the sequence. The overall random nature of the SB integration process makes it very attractive for mutagenesis [50] [51] [52] or oncogene delivery 53 studies. It also appears to provide a safer integration system for human gene therapy compared with retroviruses that display more preference for integration near actively transcribed genes. 46 Safety can likely be increased further by delivery of the SB transposase as a mRNA, shortening its expression duration. 54 It is not clear at this point if the integrated transgene expression cassettes prevent the slow loss of expression seen with non-integrating vectors after 6-12 months. 55 Longevity of expression is also influenced by the methylation status of the pDNA. Expression vectors produced in bacteria contain numerous unmethylated CpG dinucleotides, which may generate a proinflammatory cytokine response through toll-like receptor-9 signaling. Upon in vivo CpG methylation, transgene expression may be suppressed by methyl-CpG binding proteins. These responses can significantly decrease the effectiveness of the gene therapy, but have been mainly associated with pDNA complexed with cationic delivery vehicles such as liposomes. HTV delivery of CMV-based pDNA vectors with significantly reduced numbers of CpG dinucleotides resulted in significantly higher and stable expression of factor IX and a-galactosidase transgenes. 20 Linearization of the CpG-repleted vector did not further improve expression level or duration. This suggests that a more widespread use of CpG-replete vectors will result in better non-viral gene therapies. HTV delivery has also been used to corroborate enhancer function of genomic elements identified by comparative genomic analysis 56 and the evaluation of a bidirectional two-step amplification expression vector. 57 
Creation of disease models by HTV delivery
We anticipate that hydrodynamic delivery methods will be increasingly used to generate animal disease models. HTV of hepatitis B virus coding plasmids has finally enabled the study of this virus' replication in vivo. [58] [59] [60] Other viruses that are difficult to introduce into research animals, because of either receptor incompatibilities or safety issues, may similarly be delivered as a genomic expression cassette by HTV injection. Extensive genomic and biological studies of viruses are thus enabled. Other disease models may be created by the expression of disease causing proteins (e.g., dominant-negative effects), such as Z-type AAT that is retained in hepatocytes, forming intracytoplasmic inclusions.
Creation of non-heritable transgenic research animals by hydrodynamic delivery
The transient or sustained expression of proteins following hydrodynamic delivery can be used to study these proteins in similar manner as transgenics animals. We propose to refer to such models as non-heritable transgenics (nh-transgenics). In general, the characteristics of nh-transgenics include the short-or long-term expression of one or more native or non-native transgenes with appropriate physiological responses. For instance, in our own work we have observed long-term expression of apolipoprotein E (ApoE) (HTV delivery) correcting the lipidemia of ApoE(À/À) knockout mice (unpublished data). We also observed the induction of antibody responses against expressed xenogeneic transgenes following the HTV or HLV delivery. 61 Hydrodynamic delivery of siRNAs can also create nh-transgenic knockdown animals (see below). Zeini et al. 62 used the nh-transgenic approach to study the role of hepatic nitric oxide in liver regeneration after partial hepatectomy. For this purpose, they created NOS 2 -expressing mice by HTV pDNA delivery to the liver. Zhang et al. 63 studied modifications of the interleukin (IL)-2 secretion signal in vivo by HTV delivery of different IL-12 expression vectors. A similar study using conventional transgenics or protein delivery would have taken considerably longer to complete.
Study of the immune response by HTV delivery
The immune system involves a highly complex system with multiple antigen-presenting cell types, effector cells and signaling molecules. Such a system can at this time only be effectively investigated in vivo. Hydrodynamic delivery of antigens or cytokines is ideally suited for immunological investigations. Genetic immunization is an attractive approach to generate antibodies because native proteins are expressed in vivo with normal posttranscriptional modifications, avoiding time-consuming and costly antigen isolation or synthesis. We have shown that delivery of antigen expression vectors by HTV and HLV generated high-titer, antigen-specific antibodies with an overall success rate of Western blot detectable antibodies of 78 and 92%, respectively. 61 High-titer antibodies in mice, rats and rabbits were typically present after three HTV pDNA deliveries, 5 weeks after the initial injection. For HLV pDNA delivery, two deliveries were sufficient to induce high-titer antibody levels. HTV delivery was less successful at generating antibodies directed against secreted proteins as compared with HLV delivery.
Genetic immunization is eminently suited to generate antibodies against post-translationally modified antigens. We demonstrated this by HTV delivery of Ki67, a nuclear protein expressed exclusively in proliferating cells. 11 Its localization within the interphase nucleus and on condensed mitotic chromosomes during mitosis is regulated by cell cycle-specific kinases and phosphatases. Generation of monoclonal antibody producing hybridomas following a series of HTV immunizations resulted in 960 wells of fused hybridomas, of which 164 passed the initial enzyme-linked immunosorbent assay In a more stringent screen based on immunocytochemistry and Western blotting, 46 of these positive hybridoma lines reacted with specific phosphorylationdependent Ki-67 epitopes present only at certain stages of the cell cycle. For example, antibodies were isolated that stain the perinucleolar region in interphase cells, but cannot recognize Ki-67 when it is hyperphosphorylated during mitosis. Other antibodies reacted strongly with the mitotic form of the protein or stained intensely all forms of Ki-67 and others that were able to distinguish even the various stages of mitosis. Immunization with bacterially produced, non-phosphorylated recombinant proteins would not have yielded such an extensive palette of antibodies that enables the study of the dynamic changes of this protein during the cell cycle.
Hydrodynamic delivery of antigen expression vectors not only induces a humoral response, but also a cellular response. HTV delivery and expression of the herpes simplex virus type 1 (HSV-1) glycoprotein B (gB) to Balb/c mice induced significant elevation in neutralizing antibody against HSV-1 as well as cytotoxic T-lymphocyte activity and proliferative response for HSV-1. 64 The gB gene vaccination significantly protected the mice from subsequent intraperitoneal challenge with a lethal dose of HSV-1, which killed all the animals given control plasmid or saline. The protective activity was correlated with the dose of the plasmid inoculated, the survival rate reaching 83% in mice vaccinated with 5 mg of pDNA. The vaccinated mice were also protected from latent HSV infection. Finally, other studies have reported methods to activate immune cells by IL-2 pDNA delivery, 37 the effects of IL-21 on B, natural killer (NK) and NKT cell differentiation 35, 65, 66 and the role of matrix metalloproteinases in recruitment of antigen-nonspecific mononuclear cells. 67 RNAi in vivo enabled by hydrodynamic delivery of siRNA and siRNA expression cassettes It was shown previously that hydrodynamic delivery methods are very effective at transferring siRNAs. Following HTV delivery of fluorescently labeled siRNA, about 50% of hepatocytes demonstrated uptake with cytoplasmic staining and nuclear accumulation. 3 An alternative approach to enabling RNAi in vivo is by delivery of siRNA expression cassettes. We compared the efficacy and longevity of target gene knockdown from siRNA expression cassettes contained in plasmids, polymerase chain reaction (PCR)-generated linear constructs or PCR constructs containing 'dumbbell' ends using the HTV delivery method. 45 Plasmid siRNA expression constructs were more effective than PCR constructs for target gene knockdown. The efficacy of the PCR constructs was improved by addition of short extensions beyond the transcription termination signal and greatly improved by addition of dumbbell ends. Constructs containing the H1 promoter were significantly less effective in mice than those containing the U6 promoter, whereas both promoters functioned equally well in cultured cells. Target gene knockdown persisted for at least 20 weeks in mice after delivery of either PCR or plasmid siRNA expression cassettes, demonstrating the potential for long-term RNAi experiments in mice.
Importantly, in vivo RNAi provides similar molecular and phenotypic profiles as seen in conventional knockout mice. HTV delivery of siRNA to knockdown peroxisome proliferator-activated receptor alpha (Ppara) resulted in a transcript profile and metabolic phenotype that is comparable to those of Ppara (À/À) knockout mice. 68 Ppara knockdown animals developed hypoglycemia and hypertriglyceridemia, phenotypes also observed in Ppara (À/À) mice. In contrast to Ppara (À/À) mice, fasting was not required to uncover these phenotypes. Together, these data validate the utility of the RNAi approach and suggest that siRNA can be used as a complement to classical knockout technology in gene function studies.
Co-delivery of an siRNA directed against a foreign transgene with the transgene expression cassette can effectively tolerize the mice. This was elegantly demonstrated by Chu et al. 21 in a a-galactosidase A (Agal) knockout model for Fabry disease. Hydrodynamic delivery of a CMV-driven Agal vector generated antibodies against Agal. The antibody response could be attenuated by using a promoter more restricted to hepatocytes. Co-delivering an Agal siRNA resulted in a 2-log decrease in initial expression that then increased over the next few weeks to levels generated by the pDNA alone. This strategy led to both attenuated antibodies and an immune status approximating tolerance to Agal, suggesting that such an approach might have clinical utility for genetic diseases. Therapeutic RNAi applications have been shown by inhibition of hepatitis B virus 59 and hepatitis C virus 69 replication, combining viral pDNA and siRNA or shRNA HTV delivery. Yokoi et al. 70 delivered conventional connective tissue growth factor antisense oligonucleotides hydrodynamically into the renal vein and demonstrated a markedly attenuated induction of connective tissue growth factor, fibronectin, fibronectin ED-A and a1(I) collagen genes in the kidney interstitium.
Hydrodynamic delivery of viral vectors increases gene transfer efficiency
The physical nature of the hydrodynamic delivery technique not only allows for efficient transfer of naked pDNA, but, somewhat ironically, also of viral vectors. HTV delivery of a feline immunodeficiency-based lentiviral expressing luciferase under control of the hAAT promoter resulted in high levels of gene expression exclusively in the liver for over 7 months. 71 Expression levels were at least fivefold over dose obtained after a non-hydrodynamic delivery of the same virus dose. Similar results were obtained with a simian virus 40-based vector. 72 
Prospects
In a previous Progress and Prospects article on naked DNA transfer, 73 we predicted increasing use of non-viral gene transfer methods, especially HTV delivery in mice for rapid testing of expression vectors and gene therapy approaches. As highlighted above, hydrodynamic delivery, especially the tail vein procedure, has established itself as an important tool for enabling in vivo biological studies. It can be expected that the number of studies employing this gene transfer method will expand Hydrodynamic gene delivery H Herweijer and JA Wolff significantly, not only in rodents but also in larger research animals. We anticipate that hydrodynamic delivery methods will be increasingly used to generate animal disease models. It is also starting to be recognized that hydrodynamic delivery is a reliable method for delivering siRNAs to research animals. We had previously anticipated a rapid progression toward in vivo RNAi studies. 73 With a better understanding of siRNA delivery and RNAi in general, we expect significant progress in this area. The most exciting development for hydrodynamic delivery, and probably the field of gene therapy, remains the initiation of the first clinical trials employing the HLV technique. Plans are advancing to test HLV delivery of dystrophin into the arms of Duchenne muscular dystrophy patients. The objectives of this study are to establish safety of the delivery procedure and potential to transfect and express dystrophin in human muscle cells. Once safety and efficacy of HLV in humans has been established, a great number of other applications can be envisioned.
